Brexit Finally Here But Uncertainty Not Over For Biopharma
Doubts Persist On Regulatory Alignment And Migration
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
You may also be interested in...
Company suspends enrolment to trials as coronavirus travel restrictions bite.
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
Huge economic shock to sector could be quickly alleviated by early payment of R&D Tax Credits, says BIA.